Update shared on 04 Nov 2025
Fair value Increased 5.56%Analysts have raised their price target for Rani Therapeutics Holdings from $9.00 to $9.50, citing modest adjustments in future earnings expectations and profit margin outlook.
What's in the News
- Rani Therapeutics Holdings announced it will present preclinical data on its RaniPill capsule at ObesityWeek 2025. The data demonstrates oral semaglutide bioequivalence and similar weight loss effects as injections in dogs (Key Developments).
- The company entered into a Collaboration and License Agreement with Chugai Pharmaceutical for development and commercialization of an oral product. The deal terms are potentially worth up to $1.085 billion (Key Developments).
- Rani Therapeutics closed a private placement transaction on October 23, 2025 (Key Developments).
- A major securities purchase agreement was announced, resulting in gross proceeds of approximately $60.3 million. The agreement included participation from institutional and accredited investors, and warrants are linked to stockholder approval (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $9 to $9.50.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth forecast has decreased notably from 171.5% to 160.4%.
- Net Profit Margin projection is virtually steady, moving slightly from 22.05% to 22.06%.
- Future P/E ratio estimate has increased from 120.0x to 143.4x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.